Search

Your search for "vvos" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Reschedule Release of Q2 2022 Financial Results

August 15, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has announced that it will be rescheduling the release of its Q2 2022 financial results, which is for the period ended June 30, 2022; […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 2022 Call to Discuss Financial Results

August 9, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will release its second quarter 2022 financial results on Aug. 15, 2022, after market close. In conjunction with that, the company has also scheduled […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives Regulatory Clearances in Australia for Line of Oral Appliances

July 14, 2022

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has been cleared to treat obstructive sleep apnea in Australia; the clearance allows the company to treat all ages, regarding of severity. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters Strategic Distribution Agreement with GM Instruments

June 29, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its entry into an exclusive agreement with GM Instruments Ltd. for the distribution of GM Instruments’ NR6 Rhinomanometer, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Presents Sleep Apnea Study Results at Annual SLEEP 2022 Event

June 14, 2022

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, shared results from its retrospective study during SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies. Vivos Medical Advisory Board member […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Annual SLEEP 2022 Event

May 26, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will be attending and presenting at SLEEP 2022. The event is the annual meeting of the Associated […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2021 Financial, Operational Report

May 17, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the first quarter ended March 31, 2022. Highlights […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2022 Results, Conference Call

April 28, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced plans to release its financial results for the first quarter ended March […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens Third US Multidisciplinary Sleep Apnea Clinic

April 26, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced that Vivos’ medical integration division will open its third U.S. multidisciplinary sleep apnea clinic […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, Full-Year 2021 Financial, Operational Report

April 1, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the fourth quarter and full year ended Dec. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Call to Review Q4, FY 2021 Financial Results

March 31, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, has scheduled a conference call to discuss financial results that will be reported today after market close. The financial results will […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Selected Among ‘World’s Most Innovative Companies’ by Fast Company Magazine

March 8, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. Vivos Therapeutics today announced that Fast Company magazine has selected Vivos and its novel and proprietary technology for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Rebrands Proprietary Offering of Clinical Treatment Devices, Modalities and Protocols

March 3, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced a rebranding of its proprietary offering of clinical treatment devices, modalities and protocols, now […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Participate in Investor Conferences

March 2, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, will be presenting at two upcoming investor conferences. According to the company, VVOS CEO Kirk Huntsman will participate in the Q1 […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate in 2022 World Sleep Congress

February 24, 2022

Vivos Therapeutics (NASDAQ: VVOS) Medical Advisor Board has been invited to present at the upcoming World Sleep Congress. The event, slated for March 11–16, 2022, will be held in Rome. Members of the board will be presenting a summary review of sleep-therapy data from patients treated with the Vivos Method. Vivos is a medical technology […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Files for US Patent on Proprietary New and Enhanced Clinical Protocols

January 27, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced the filing of a U.S. patent application related to certain new and enhanced clinical methods and protocols developed within its proprietary Vivos Method treatment […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Info Gathered during Sleep Apnea Diagnostic Testing

January 19, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, is reporting significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (“HST”) during the three-month period that ended Dec. 31, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) mmRNA Device Now Covered by, Billable to Medicare

December 14, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that it has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding (“PDAC”) contractor for its mmRNA (modified […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Officially Registers with Health Canada

December 9, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has registered with Health Canada, a key step in being able to manufacture and sell its proprietary sleep disorder, snoring and sleep apnea appliances […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

December 3, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q3 2021 Financial, Operational Report

November 16, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Q4 Virtual Investor Summit

November 15, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The summit is scheduled for Nov. 17, 2021. Vivos CEO Kirk Huntsman, chief financial officer Brad Amman, and investor relations officer […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Scheduled Release of Q3 2021 Financial Results, Conference Call

November 9, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it plans to release financial results for the third quarter ended Sept. 30, 2021, after market close on Monday, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

October 22, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference

October 20, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution

October 19, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution

October 18, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

October 13, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology

September 23, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference

September 22, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment

August 26, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance

August 23, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study

August 18, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

August 13, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit

August 10, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results

August 9, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

July 29, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

July 13, 2021

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

July 7, 2021

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).